期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肝癌肝移植 被引量：1

下载PDF
导出
摘要 在我国，超过80％的肝细胞癌（简称肝癌，HCC）都伴有肝硬化，手术可切除率仅为20％左右。对于有肝硬化基础的小肝癌，最佳治疗手段则是肝移植，因为肝移植不仅治愈了肝癌，同时还治愈了肝硬化。我国肝癌肝移植占肝移植总数近一半，在欧美国家的比例也有升高趋势，其疗效也不断提高。本文主要介绍近年来在肝癌肝移植适应证、移植前的肿瘤治疗、个体化免疫抑制方案、肝癌复发的影响因素以及复发的治疗等方面的进展。
作者 汪国营 杨扬
机构地区 中山大学附属第三医院肝脏外科暨肝脏移植中心 中山大学器官移植研究所
出处 《肝胆外科杂志》 2013年第4期241-244,共4页 Journal of Hepatobiliary Surgery
关键词 肝癌 移植
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus de?ceased donor transplantation. Heputology ,2011 ,53 (5) : 1570 - 9.
  • 2陈规划,易述红.肝癌肝移植术前的肿瘤降期治疗[J].肝胆外科杂志,2011,19(5):324-326. 被引量：3
  • 3Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide a?bout liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE? J Hepatol, 2013 ,59 (2) :279 -84.
  • 4Hodriguez-Peralvarez M, Tsochatzis E, Naveas MC, et al. Reduced Exposure to Calcineurin Inhibitors Early Mter Liver Transplantation Prevents Recurrence of Hepatocellular Carcinoma. J Hepatol, 2013.
  • 5Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepa?tocellular carcinoma. Aliment Pharmacol Ther, 2013 ,37 (4) :411 - 9.
  • 6安玉玲,张婷婷,蔡常洁.西罗莫司用于治疗肝癌肝移植术后肿瘤复发患者的疗效分析[J].器官移植,2011,2(2):73-76. 被引量：15
  • 7Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective random?ised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer ,2010,10: 190.
  • 8Kornberg A, Kupper B, Tannapfel A, et al. Patients with non-] 18 F J fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl, 2012,18(1) :53 -6J.
  • 9Li MR, Chen GH, Cai CJ, et al. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion, 2011 ,84 (2) : 134 - 41.
  • 10Siegel AB, Lim EA, Wang S, et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation, 2012 ,94 ( 5) : 539 - 43.

二级参考文献14

  • 1Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China.Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J].Hepatobiliary & Pancreatic Diseases International,2012,11(5):458-466. 被引量：29
  • 2郑克立,王长希,陈立中,唐孝达,范昱,闵志廉,齐隽,黎磊石,刘志红,季曙明.雷帕霉素联合环孢素和皮质类固醇预防肾移植急性排斥反应的临床研究[J].中华器官移植杂志,2004,25(4):240-242. 被引量：10
  • 3Jian Zhou Jia Fan Zheng Wang Zhi-Quan Wu Shuang-Jian Qiu Xiao-Wu Huang Yao Yu Jian Sun Yong-Sheng Xiao Yi-Feng He Yu-Qi Wang Zhao-You Tang.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma:Report of an initial experience[J].World Journal of Gastroenterology,2006,12(19):3114-3118. 被引量：20
  • 4汤钊猷.开展肝癌转移复发研究的意义与途径[J].中华普通外科杂志,2006,21(11):761-761. 被引量：34
  • 5Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation : an intention-to-treat analysis. Hepatology, 2008,48 : 819 - 827.
  • 6Millonig G, Graziadei IW, Freund MC, et al. Response to preopera- tive chemoembolization correlates with outcome after liver transplanta- tion in patients with hepatocellular carcinoma. Liver Transpl, 2007, 13: 272-279.
  • 7Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepato- cellular carcinoma: treatment success as defined by histologic exami- nation of the explanted liver. Radiology ,2005,234:954 -60.
  • 8Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoemboliza- tion followed by liver transplantation for hepatoeellular carcinoma im- pedes tumor progression while on the waiting list and leads to excel- lent outcome. Liver Transpl 2003 ; 9 : 557 - 563.
  • 9Llovet JM, Real MI, Mon tana X, Barcelona Liver Cancer Group. Art erial embolisation or ehemoembeli sation versus symptomatic treatment in patients with unreseetable hepatoeellular carcinoma: a ran domised controlled trial. Lancet ;2002, 359 ; 1734 - 1739.
  • 10Lewandowski,RJ, Kulik LM, Riaz A, et al. A Comparative Analysis of Transarterial Downstaging for Hepatoeellular Carcinoma: Chemoem- bolization Versus Radioembolization. Am J Transplant, 2009, 9 : 1920 - 1928.

共引文献23

同被引文献21

  • 1朱志军,高伟,孟醒初,张雅敏,蒋文涛,张建军,张玮晔,沈中阳.脂肪沉着供肝在肝脏移植中的应用[J].中华肝胆外科杂志,2005,11(9):627-629. 被引量：7
  • 2McCormack L1, Dutkowski P, E1-Badry AM, et al. Liver transplantation using fatty livers : always feasible? [ J ]. Hepatol, 2011, 54(5) : 1055-1062.
  • 3Chui AK, Haghighi K, Painter D, et al. Donaor fatty (steatotic)liver allografts in orthotopie liver transplantation [ J ]. Transplant Proc, 1998, 30(7): 3286-3287.
  • 4Chavin KD, Taber DJ, Norcross M, et al. Safe use of highly steatotic livers by utilizingadonor/recipient clinical algorithm [ J 1. Clin Transplant, 2013, 27(5): 732-741.
  • 5DeAlwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears [ J ]. J Hepatol, 2008, 48 ( 1 ) : 104-112.
  • 6Petrowsky H, McCormack L, Trujillo M, et al. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus isehemic preconditioning with continuous clamping for major liver resection [ J~. Ann Surg, 2006, 244 (6) : 921- 928.
  • 7Angele MK, Rentsch M, Hartl WH, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation [ J 1. Am J Surg, 2008, 195(2) : 214-220.
  • 8Marsman WA, Wiesner RH, Rodriguez L, et al. Use of fatty donor liver is associated with diminished early patient and graft survival[J1. Transplantation, 1996, 62(9) : 1246-1251.
  • 9Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopie liver transplantation[J~. Liver Transpl, 2003, 9(5) : 500-505.
  • 10Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver, incorporating macrosteatosis into high-risk donor assessment [ J ]. Liver Transpl, 2010, 16(7) : 874-884.

引证文献1

肝胆外科杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部